Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 123 entries
Sorted by: Best Match Show Resources per page
Wind Profiling in the Lower Atmosphere from Wind-Induced Perturbations to Multirotor UAS.

Sensors (Basel, Switzerland)

González-Rocha J, De Wekker SFJ, Ross SD, Woolsey CA.
PMID: 32121450
Sensors (Basel). 2020 Feb 29;20(5). doi: 10.3390/s20051341.

We present a model-based approach to estimate the vertical profile of horizontal wind velocity components using motion perturbations of a multirotor unmanned aircraft system (UAS) in both hovering and steady ascending flight. The state estimation framework employed for wind...

Cite
González-Rocha J, De Wekker SFJ, Ross SD, et al. Wind Profiling in the Lower Atmosphere from Wind-Induced Perturbations to Multirotor UAS. Sensors (Basel). 2020;20(5)doi: 10.3390/s20051341.
González-Rocha, J., De Wekker, S. F. J., Ross, S. D., & Woolsey, C. A. (2020). Wind Profiling in the Lower Atmosphere from Wind-Induced Perturbations to Multirotor UAS. Sensors (Basel, Switzerland), 20(5), . https://doi.org/10.3390/s20051341
González-Rocha, Javier, et al. "Wind Profiling in the Lower Atmosphere from Wind-Induced Perturbations to Multirotor UAS." Sensors (Basel, Switzerland) vol. 20,5 (2020). doi: https://doi.org/10.3390/s20051341
González-Rocha J, De Wekker SFJ, Ross SD, Woolsey CA. Wind Profiling in the Lower Atmosphere from Wind-Induced Perturbations to Multirotor UAS. Sensors (Basel). 2020 Feb 29;20(5). doi: 10.3390/s20051341. PMID: 32121450; PMCID: PMC7085559.
Copy Download .nbib Format: NLM
Coordinated Unmanned Aircraft System (UAS) and Ground-Based Weather Measurements to Predict Lagrangian Coherent Structures (LCSs).

Sensors (Basel, Switzerland)

Nolan PJ, Pinto J, González-Rocha J, Jensen A, Vezzi CN, Bailey SCC, de Boer G, Diehl C, Laurence R, Powers CW, Foroutan H, Ross SD, Schmale DG.
PMID: 30558335
Sensors (Basel). 2018 Dec 15;18(12). doi: 10.3390/s18124448.

Concentrations of airborne chemical and biological agents from a hazardous release are not spread uniformly. Instead, there are regions of higher concentration, in part due to local atmospheric flow conditions which can attract agents. We equipped a ground station...

Cite
Nolan PJ, Pinto J, González-Rocha J, et al. Coordinated Unmanned Aircraft System (UAS) and Ground-Based Weather Measurements to Predict Lagrangian Coherent Structures (LCSs). Sensors (Basel). 2018;18(12)doi: 10.3390/s18124448.
Nolan, P. J., Pinto, J., González-Rocha, J., Jensen, A., Vezzi, C. N., Bailey, S. C. C., de Boer, G., Diehl, C., Laurence, R., Powers, C. W., Foroutan, H., Ross, S. D., & Schmale, D. G. (2018). Coordinated Unmanned Aircraft System (UAS) and Ground-Based Weather Measurements to Predict Lagrangian Coherent Structures (LCSs). Sensors (Basel, Switzerland), 18(12), . https://doi.org/10.3390/s18124448
Nolan, Peter J, et al. "Coordinated Unmanned Aircraft System (UAS) and Ground-Based Weather Measurements to Predict Lagrangian Coherent Structures (LCSs)." Sensors (Basel, Switzerland) vol. 18,12 (2018). doi: https://doi.org/10.3390/s18124448
Nolan PJ, Pinto J, González-Rocha J, Jensen A, Vezzi CN, Bailey SCC, de Boer G, Diehl C, Laurence R, Powers CW, Foroutan H, Ross SD, Schmale DG. Coordinated Unmanned Aircraft System (UAS) and Ground-Based Weather Measurements to Predict Lagrangian Coherent Structures (LCSs). Sensors (Basel). 2018 Dec 15;18(12). doi: 10.3390/s18124448. PMID: 30558335; PMCID: PMC6308849.
Copy Download .nbib Format: NLM
Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors.

JNCI cancer spectrum

Kerns SL, Fung C, Fossa SD, Dinh PC, Monahan P, Sesso HD, Frisina RD, Feldman DR, Hamilton RJ, Vaughn D, Martin N, Huddart R, Kollmannsberger C, Sahasrabudhe D, Ardeshir-Rouhani-Fard S, Einhorn L, Travis LB.
PMID: 32704617
JNCI Cancer Spectr. 2020 Mar 20;4(4):pkaa022. doi: 10.1093/jncics/pkaa022. eCollection 2020 Aug.

BACKGROUND: Few data exist on the relationship of cisplatin-related adverse health outcomes (AHOs) with disability, unemployment, and self-reported health (SRH) among testicular cancer survivors (TCS).METHODS: A total of 1815 TCS at least 1 year postchemotherapy underwent clinical examination and...

Cite
Kerns SL, Fung C, Fossa SD, et al. Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. JNCI Cancer Spectr. 2020;4(4):pkaa022doi: 10.1093/jncics/pkaa022.
Kerns, S. L., Fung, C., Fossa, S. D., Dinh, P. C., Monahan, P., Sesso, H. D., Frisina, R. D., Feldman, D. R., Hamilton, R. J., Vaughn, D., Martin, N., Huddart, R., Kollmannsberger, C., Sahasrabudhe, D., Ardeshir-Rouhani-Fard, S., Einhorn, L., & Travis, L. B. (2020). Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. JNCI cancer spectrum, 4(4), pkaa022. https://doi.org/10.1093/jncics/pkaa022
Kerns, Sarah L, et al. "Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors." JNCI cancer spectrum vol. 4,4 (2020): pkaa022. doi: https://doi.org/10.1093/jncics/pkaa022
Kerns SL, Fung C, Fossa SD, Dinh PC, Monahan P, Sesso HD, Frisina RD, Feldman DR, Hamilton RJ, Vaughn D, Martin N, Huddart R, Kollmannsberger C, Sahasrabudhe D, Ardeshir-Rouhani-Fard S, Einhorn L, Travis LB. Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. JNCI Cancer Spectr. 2020 Mar 20;4(4):pkaa022. doi: 10.1093/jncics/pkaa022. eCollection 2020 Aug. PMID: 32704617; PMCID: PMC7368467.
Copy Download .nbib Format: NLM
Development of Folate Receptor-Targeted PET Radiopharmaceuticals for Tumor Imaging-A Bench-to-Bedside Journey.

Cancers

Boss SD, Ametamey SM.
PMID: 32527010
Cancers (Basel). 2020 Jun 09;12(6). doi: 10.3390/cancers12061508.

The folate receptor-α (FR-α) is overexpressed in many epithelial cancers, including ovary, uterus, kidneys, breast, lung, colon and prostate carcinomas, but shows limited expression in normal tissues such as kidneys, salivary glands, choroid plexus and placenta. FR-α has therefore...

Cite
Boss SD, Ametamey SM. Development of Folate Receptor-Targeted PET Radiopharmaceuticals for Tumor Imaging-A Bench-to-Bedside Journey. Cancers (Basel). 2020;12(6)doi: 10.3390/cancers12061508.
Boss, S. D., & Ametamey, S. M. (2020). Development of Folate Receptor-Targeted PET Radiopharmaceuticals for Tumor Imaging-A Bench-to-Bedside Journey. Cancers, 12(6), . https://doi.org/10.3390/cancers12061508
Boss, Silvan D, and Ametamey, Simon Mensah. "Development of Folate Receptor-Targeted PET Radiopharmaceuticals for Tumor Imaging-A Bench-to-Bedside Journey." Cancers vol. 12,6 (2020). doi: https://doi.org/10.3390/cancers12061508
Boss SD, Ametamey SM. Development of Folate Receptor-Targeted PET Radiopharmaceuticals for Tumor Imaging-A Bench-to-Bedside Journey. Cancers (Basel). 2020 Jun 09;12(6). doi: 10.3390/cancers12061508. PMID: 32527010; PMCID: PMC7352234.
Copy Download .nbib Format: NLM
Beach-level 24-hour forecasts of Florida red tide-induced respiratory irritation.

Harmful algae

Ross SD, Fish J, Moeltner K, Bollt EM, Bilyeu L, Fanara T.
PMID: 35016762
Harmful Algae. 2022 Jan;111:102149. doi: 10.1016/j.hal.2021.102149. Epub 2021 Dec 12.

An accurate forecast of the red tide respiratory irritation level would improve the lives of many people living in areas affected by algal blooms. Using a decades-long database of daily beach conditions, two conceptually different models to forecast the...

Cite
Ross SD, Fish J, Moeltner K, et al. Beach-level 24-hour forecasts of Florida red tide-induced respiratory irritation. Harmful Algae. 2021;111:102149doi: 10.1016/j.hal.2021.102149.
Ross, S. D., Fish, J., Moeltner, K., Bollt, E. M., Bilyeu, L., & Fanara, T. (2022). Beach-level 24-hour forecasts of Florida red tide-induced respiratory irritation. Harmful algae, 111102149. https://doi.org/10.1016/j.hal.2021.102149
Ross, Shane D, et al. "Beach-level 24-hour forecasts of Florida red tide-induced respiratory irritation." Harmful algae vol. 111 (2022): 102149. doi: https://doi.org/10.1016/j.hal.2021.102149
Ross SD, Fish J, Moeltner K, Bollt EM, Bilyeu L, Fanara T. Beach-level 24-hour forecasts of Florida red tide-induced respiratory irritation. Harmful Algae. 2022 Jan;111:102149. doi: 10.1016/j.hal.2021.102149. Epub 2021 Dec 12. PMID: 35016762.
Copy Download .nbib Format: NLM
Associations between childhood maltreatment, poor sleep, and prenatal distress in pregnant adolescents.

Development and psychopathology

Foss S, Gustafsson HC, Berry OO, Hipwell AE, Werner EA, Peterson BS, Monk C.
PMID: 33551015
Dev Psychopathol. 2021 Feb 08;1-10. doi: 10.1017/S0954579420002163. Epub 2021 Feb 08.

Childhood maltreatment (CM) is a known risk factor for adolescent pregnancy. Sleep disturbances and psychological distress, both common negative sequelae of CM, often co-occur during pregnancy, although directionality remains unclear. Furthermore, little is known about how CM affects sleep-distress...

Cite
Foss S, Gustafsson HC, Berry OO, et al. Associations between childhood maltreatment, poor sleep, and prenatal distress in pregnant adolescents. Dev Psychopathol. 2021;1-10doi: 10.1017/S0954579420002163.
Foss, S., Gustafsson, H. C., Berry, O. O., Hipwell, A. E., Werner, E. A., Peterson, B. S., & Monk, C. (2021). Associations between childhood maltreatment, poor sleep, and prenatal distress in pregnant adolescents. Development and psychopathology, 1-10. https://doi.org/10.1017/S0954579420002163
Foss, Sophie, et al. "Associations between childhood maltreatment, poor sleep, and prenatal distress in pregnant adolescents." Development and psychopathology vol. (2021): 1-10. doi: https://doi.org/10.1017/S0954579420002163
Foss S, Gustafsson HC, Berry OO, Hipwell AE, Werner EA, Peterson BS, Monk C. Associations between childhood maltreatment, poor sleep, and prenatal distress in pregnant adolescents. Dev Psychopathol. 2021 Feb 08;1-10. doi: 10.1017/S0954579420002163. Epub 2021 Feb 08. PMID: 33551015; PMCID: PMC8349382.
Copy Download .nbib Format: NLM
Residual Platinum Concentrations in Post-Cancer Chemotherapy and Healthy Control Populations Using an Automated, 96-Well Plate Method and Inductively Coupled Plasma Mass Spectrometry.

The journal of applied laboratory medicine

Strathmann FG, Travis LB, Ardeshirrouhanifard S, Fossa SD, Moody S, Clarke D, Law CL.
PMID: 33626787
J Appl Lab Med. 2016 Sep 01;1(2):143-151. doi: 10.1373/jalm.2016.020081.

BACKGROUND: Platinating agents are among the most commonly used cytotoxic drugs worldwide. It is recognized that Pt concentration can remain significantly increased in serum up to 20 years after completion of chemotherapy, with levels related to late treatment effects.METHODS:...

Cite
Strathmann FG, Travis LB, Ardeshirrouhanifard S, et al. Residual Platinum Concentrations in Post-Cancer Chemotherapy and Healthy Control Populations Using an Automated, 96-Well Plate Method and Inductively Coupled Plasma Mass Spectrometry. J Appl Lab Med. 2016;1(2):143-151doi: 10.1373/jalm.2016.020081.
Strathmann, F. G., Travis, L. B., Ardeshirrouhanifard, S., Fossa, S. D., Moody, S., Clarke, D., & Law, C. L. (2016). Residual Platinum Concentrations in Post-Cancer Chemotherapy and Healthy Control Populations Using an Automated, 96-Well Plate Method and Inductively Coupled Plasma Mass Spectrometry. The journal of applied laboratory medicine, 1(2), 143-151. https://doi.org/10.1373/jalm.2016.020081
Strathmann, Frederick G, et al. "Residual Platinum Concentrations in Post-Cancer Chemotherapy and Healthy Control Populations Using an Automated, 96-Well Plate Method and Inductively Coupled Plasma Mass Spectrometry." The journal of applied laboratory medicine vol. 1,2 (2016): 143-151. doi: https://doi.org/10.1373/jalm.2016.020081
Strathmann FG, Travis LB, Ardeshirrouhanifard S, Fossa SD, Moody S, Clarke D, Law CL. Residual Platinum Concentrations in Post-Cancer Chemotherapy and Healthy Control Populations Using an Automated, 96-Well Plate Method and Inductively Coupled Plasma Mass Spectrometry. J Appl Lab Med. 2016 Sep 01;1(2):143-151. doi: 10.1373/jalm.2016.020081. PMID: 33626787.
Copy Download .nbib Format: NLM
Gas-Phase Optical Detection of 3-Ethynylcyclopentenyl: A Resonance-Stabilized C.

Journal of the American Chemical Society

Reilly NJ, Kokkin DL, Ward ML, Flores J, Ross SD, McCaslin LM, Stanton JF.
PMID: 32396343
J Am Chem Soc. 2020 Jun 10;142(23):10400-10411. doi: 10.1021/jacs.0c01579. Epub 2020 May 27.

The 3-ethynylcyclopentenyl radical (3ecpr) has been identified as the carrier of an electronic spectrum with origin at 21792 cm

Cite
Reilly NJ, Kokkin DL, Ward ML, et al. Gas-Phase Optical Detection of 3-Ethynylcyclopentenyl: A Resonance-Stabilized C. J Am Chem Soc. 2020;142(23):10400-10411doi: 10.1021/jacs.0c01579.
Reilly, N. J., Kokkin, D. L., Ward, M. L., Flores, J., Ross, S. D., McCaslin, L. M., & Stanton, J. F. (2020). Gas-Phase Optical Detection of 3-Ethynylcyclopentenyl: A Resonance-Stabilized C. Journal of the American Chemical Society, 142(23), 10400-10411. https://doi.org/10.1021/jacs.0c01579
Reilly, Neil J, et al. "Gas-Phase Optical Detection of 3-Ethynylcyclopentenyl: A Resonance-Stabilized C." Journal of the American Chemical Society vol. 142,23 (2020): 10400-10411. doi: https://doi.org/10.1021/jacs.0c01579
Reilly NJ, Kokkin DL, Ward ML, Flores J, Ross SD, McCaslin LM, Stanton JF. Gas-Phase Optical Detection of 3-Ethynylcyclopentenyl: A Resonance-Stabilized C. J Am Chem Soc. 2020 Jun 10;142(23):10400-10411. doi: 10.1021/jacs.0c01579. Epub 2020 May 27. PMID: 32396343.
Copy Download .nbib Format: NLM
Combining functional metagenomics and glycoanalytics to identify enzymes that facilitate structural characterization of sulfated N-glycans.

Microbial cell factories

Chuzel L, Fossa SL, Boisvert ML, Cajic S, Hennig R, Ganatra MB, Reichl U, Rapp E, Taron CH.
PMID: 34419057
Microb Cell Fact. 2021 Aug 21;20(1):162. doi: 10.1186/s12934-021-01652-w.

BACKGROUND: Sulfate modification of N-glycans is important for several biological functions such as clearance of pituitary hormones or immunoregulation. Yet, the prevalence of this N-glycan modification and its functions remain largely unexplored. Characterization of N-glycans bearing sulfate modifications is...

Cite
Chuzel L, Fossa SL, Boisvert ML, et al. Combining functional metagenomics and glycoanalytics to identify enzymes that facilitate structural characterization of sulfated N-glycans. Microb Cell Fact. 2021;20(1):162doi: 10.1186/s12934-021-01652-w.
Chuzel, L., Fossa, S. L., Boisvert, M. L., Cajic, S., Hennig, R., Ganatra, M. B., Reichl, U., Rapp, E., & Taron, C. H. (2021). Combining functional metagenomics and glycoanalytics to identify enzymes that facilitate structural characterization of sulfated N-glycans. Microbial cell factories, 20(1), 162. https://doi.org/10.1186/s12934-021-01652-w
Chuzel, Léa, et al. "Combining functional metagenomics and glycoanalytics to identify enzymes that facilitate structural characterization of sulfated N-glycans." Microbial cell factories vol. 20,1 (2021): 162. doi: https://doi.org/10.1186/s12934-021-01652-w
Chuzel L, Fossa SL, Boisvert ML, Cajic S, Hennig R, Ganatra MB, Reichl U, Rapp E, Taron CH. Combining functional metagenomics and glycoanalytics to identify enzymes that facilitate structural characterization of sulfated N-glycans. Microb Cell Fact. 2021 Aug 21;20(1):162. doi: 10.1186/s12934-021-01652-w. PMID: 34419057; PMCID: PMC8379841.
Copy Download .nbib Format: NLM
Potential Use of Gluconate in Cancer Therapy.

Frontiers in oncology

Mycielska ME, Mohr MTJ, Schmidt K, Drexler K, Rümmele P, Haferkamp S, Schlitt HJ, Gaumann A, Adamski J, Geissler EK, Anand A, Fosso S, Gnanzou D.
PMID: 31275855
Front Oncol. 2019 Jun 19;9:522. doi: 10.3389/fonc.2019.00522. eCollection 2019.

We have recently discovered that cancer cells take up extracellular citrate through plasma membrane citrate transporter (pmCiC) and advantageously use citrate for their metabolism. Citrate uptake can be blocked with gluconate and this results in decreased tumor growth and...

Cite
Mycielska ME, Mohr MTJ, Schmidt K, et al. Potential Use of Gluconate in Cancer Therapy. Front Oncol. 2019;9:522doi: 10.3389/fonc.2019.00522.
Mycielska, M. E., Mohr, M. T. J., Schmidt, K., Drexler, K., Rümmele, P., Haferkamp, S., Schlitt, H. J., Gaumann, A., Adamski, J., Geissler, E. K., Anand, A., Fosso, S., & Gnanzou, D. (2019). Potential Use of Gluconate in Cancer Therapy. Frontiers in oncology, 9522. https://doi.org/10.3389/fonc.2019.00522
Mycielska, Maria E, et al. "Potential Use of Gluconate in Cancer Therapy." Frontiers in oncology vol. 9 (2019): 522. doi: https://doi.org/10.3389/fonc.2019.00522
Mycielska ME, Mohr MTJ, Schmidt K, Drexler K, Rümmele P, Haferkamp S, Schlitt HJ, Gaumann A, Adamski J, Geissler EK, Anand A, Fosso S, Gnanzou D. Potential Use of Gluconate in Cancer Therapy. Front Oncol. 2019 Jun 19;9:522. doi: 10.3389/fonc.2019.00522. eCollection 2019. PMID: 31275855; PMCID: PMC6593216.
Copy Download .nbib Format: NLM
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).

Clinical cancer research : an official journal of the American Association for Cancer Research

Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, Berg SL, Fox E, Adamson PC, Blaney SM, Weigel BJ, Mossé YP.
PMID: 33568345
Clin Cancer Res. 2021 Jul 01;27(13):3543-3548. doi: 10.1158/1078-0432.CCR-20-4224. Epub 2021 Feb 10.

PURPOSE: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in patients with no known curative treatments and whose tumors harbored an activating ALK alteration.PATIENTS AND...

Cite
Foster JH, Voss SD, Hall DC, et al. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021;27(13):3543-3548doi: 10.1158/1078-0432.CCR-20-4224.
Foster, J. H., Voss, S. D., Hall, D. C., Minard, C. G., Balis, F. M., Wilner, K., Berg, S. L., Fox, E., Adamson, P. C., Blaney, S. M., Weigel, B. J., & Mossé, Y. P. (2021). Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3543-3548. https://doi.org/10.1158/1078-0432.CCR-20-4224
Foster, Jennifer H, et al. "Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3543-3548. doi: https://doi.org/10.1158/1078-0432.CCR-20-4224
Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, Berg SL, Fox E, Adamson PC, Blaney SM, Weigel BJ, Mossé YP. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 Jul 01;27(13):3543-3548. doi: 10.1158/1078-0432.CCR-20-4224. Epub 2021 Feb 10. PMID: 33568345; PMCID: PMC8254744.
Copy Download .nbib Format: NLM
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.

The Lancet. Oncology

Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH.
PMID: 34895479
Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09.

BACKGROUND: Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) and...

Cite
Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2021;23(1):125-137doi: 10.1016/S1470-2045(21)00470-8.
Mauz-Körholz, C., Landman-Parker, J., Balwierz, W., Ammann, R. A., Anderson, R. A., Attarbaschi, A., Bartelt, J. M., Beishuizen, A., Boudjemaa, S., Cepelova, M., Claviez, A., Daw, S., Dieckmann, K., Fernández-Teijeiro, A., Fosså, A., Gattenlöhner, S., Georgi, T., Hjalgrim, L. L., Hraskova, A., Karlén, J., Kluge, R., Kurch, L., Leblanc, T., Mann, G., Montravers, F., Pears, J., Pelz, T., Rajić, V., Ramsay, A. D., Stoevesandt, D., Uyttebroeck, A., Vordermark, D., Körholz, D., Hasenclever, D., & Wallace, W. H. (2022). Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. The Lancet. Oncology, 23(1), 125-137. https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz, Christine, et al. "Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial." The Lancet. Oncology vol. 23,1 (2022): 125-137. doi: https://doi.org/10.1016/S1470-2045(21)00470-8
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 09. PMID: 34895479.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 123 entries